Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review

Mahmoud Abdelnabi; Yehia Saleh; Abdallah Almaghraby; Hany Girgis; Fady Gerges

doi:10.2174/1573403X17666210831142452

Back

Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review

Journal article

Peer reviewed

Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review

Mahmoud Abdelnabi, Yehia Saleh, Abdallah Almaghraby, Hany Girgis and Fady Gerges

Current cardiology reviews, Vol.18(3), pp.e310821195982-20

05/01/2022

DOI: 10.2174/1573403X17666210831142452

PMCID: PMC9615216

PMID: 34488614

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/9615216View

Open Access

Abstract

Heart Failure (HF) is among the major causes of global morbidity as well as mortality. Increased prevalence, frequent and prolonged hospitalization, rehospitalization, long-term consumption of healthcare resources, absenteeism, and death upsurge the economic burden linked to HF. For decades, Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), Beta-Blockers (BBs), and mineralocorticoid receptor antagonists (MRA), have remained the mainstay of the standard of care for HF management. Despite their proven efficacy and cost-effectiveness, HF remains a global pandemic and is still increasing in prevalence. Sacubitril/ Valsartan (SAC/VAL) is an Angiotensin Receptor/Neprilysin Inhibitor (ARNI) that proved out to be a game-changer drug in HF treatment. Recent data indicated that SAC/VAL is more efficient and can improve the overall quality of life of HF patients with reduced ejection fraction (HFrEF) with fewer side effects. It is now incorporated in the guidelines as an alternative to ACEIs or ARBs to lower morbidity in addition to mortality in HFrEF patients. This review article will discuss the current guidelines-approved indications and highlight the potential emerging indications, in addition to the currently ongoing clinical trials that will expand the use of SAC/VAL.

Quality of Life

Aminobutyrates

Angiotensin Receptor Antagonists - pharmacology

Angiotensin Receptor Antagonists - therapeutic use

Angiotensin-Converting Enzyme Inhibitors - pharmacology

Angiotensin-Converting Enzyme Inhibitors - therapeutic use

Biphenyl Compounds

Heart Failure - drug therapy

Humans

Stroke Volume

Tetrazoles - pharmacology

Tetrazoles - therapeutic use

Treatment Outcome

Valsartan - pharmacology

Valsartan - therapeutic use

Details

Title: Subtitle: Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Creators: Mahmoud Abdelnabi - Alexandria University
Yehia Saleh - Houston Methodist
Abdallah Almaghraby - Alexandria University
Hany Girgis - Jeroen Bosch Ziekenhuis
Fady Gerges - Mediclinic City Hospital
Resource Type: Journal article
Publication Details: Current cardiology reviews, Vol.18(3), pp.e310821195982-20
DOI: 10.2174/1573403X17666210831142452
PMID: 34488614
PMCID: PMC9615216
NLM abbreviation: Curr Cardiol Rev
ISSN: 1573-403X
eISSN: 1875-6557
Language: English
Date published: 05/01/2022
Academic Unit: Internal Medicine
Record Identifier: 9984756263002771

Metrics

5 Record Views

3 Times Cited - Web of Science